Profiel
Dr. Evy Lundgren-Åkerlund is a CEO, Head-Business & Administration at Xintela AB.
She is on the Board of Directors at Targinta AB.
Dr. Lundgren-Åkerlund was previously employed as a Chief Executive Officer & Head-Operations by Lund Life Science Incubator and a Vice President-Research & Development by Cartela AB.
Actieve functies van Evy Lundgren-Åkerlund
| Bedrijven | Functie | Begin |
|---|---|---|
| XINTELA AB | Founder | 01-01-2009 |
Targinta AB
 Targinta AB BiotechnologyHealth Technology Part of Xintela AB, Targinta AB develops targeting and toxin-armed antibodies for cancer. The private company is based in Lund, Sweden. Peter Ekolind has been the CEO of the Swedish company since 2022. | Director/Board Member | - |
Eerdere bekende functies van Evy Lundgren-Åkerlund
| Bedrijven | Functie | Einde |
|---|---|---|
| Lund Life Science Incubator | Chief Executive Officer | 01-01-2012 |
Cartela AB
 Cartela AB Pharmaceuticals: MajorHealth Technology Cartela AB develops therapies for arthritic diseases. It products are mainly used by osteoarthritis and rheumatoid arthritis. Its business is based on the cell surface molecules, integrants a10ß1 and a11ß1. The company was founded by Evy Lundgren-Åkerlund and Donald Gullberg in 2000 and is headquartered in Lund, Sweden. | Founder | 24-12-2008 |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| XINTELA AB | Health Technology |
| Bedrijven in privébezit | 3 |
|---|---|
Cartela AB
Cartela AB Pharmaceuticals: MajorHealth Technology Cartela AB develops therapies for arthritic diseases. It products are mainly used by osteoarthritis and rheumatoid arthritis. Its business is based on the cell surface molecules, integrants a10ß1 and a11ß1. The company was founded by Evy Lundgren-Åkerlund and Donald Gullberg in 2000 and is headquartered in Lund, Sweden. | Health Technology |
| Lund Life Science Incubator | |
Targinta AB
Targinta AB BiotechnologyHealth Technology Part of Xintela AB, Targinta AB develops targeting and toxin-armed antibodies for cancer. The private company is based in Lund, Sweden. Peter Ekolind has been the CEO of the Swedish company since 2022. | Health Technology |
